Newswise — NYU Langone Medical Center announced today that Howard A. Fine, MD, has been appointed the Anne Murnick Cogan and David H. Cogan Professor of Oncology, chief of the Division of Hematology and Medical Oncology, director of the Brain Tumor Center, and deputy director of the NYU Cancer Institute. His appointment is effective September 5, 2012.
A recognized leader in neuro-oncology and medical research, Dr. Fine joins NYU Langone from the National Cancer Institute (NCI) for Cancer Research in Bethesda, MD where he is the chief of the Neuro-Oncology Branch (NOB) and holds a joint appointment with the National Institute of Neurological Disorders and Stroke (NINDS), as an adjunct investigator. In his new role, he will have a wide range of responsibilities including directing clinical programs in solid tumor oncology, developmental therapeutics, malignant hematology and experimental hematology.
“We are delighted to welcome Dr. Fine to the NYU Langone faculty. As one of today’s leading neuro-oncologists and a visionary leader, he brings a wealth of expertise and experience in research to treat brain tumors of adults and children,” said William L. Carroll, MD, the Julie and Edward J. Minskoff Professor of Pediatrics, Department of Pediatrics, professor, Department of Pathology and director, NYU Cancer Institute at NYU Langone. “He will continue to build on the world-class care our patients have already come to expect us to deliver.”
Dr. Fine completed both his internship and his residency in Internal Medicine at the Hospital of The University of Pennsylvania. He later completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston, MA, a teaching affiliate of Harvard Medical School. Before joining the NIH in 2000, Dr. Fine was both director of the Neuro-Oncology Disease Center at Dana-Farber Cancer Institute and of the Neuro-Oncology Program at the Dana-Farber/Harvard Cancer Center. While at NCI, he developed one of the preeminent brain tumors programs in the world.
About the NYU Cancer Institute The research mission of the NYU Cancer Institute is to discover the origins of cancer and use that knowledge to eradicate the personal and societal burden of cancer in our community and around the world. Fifteen research programs are organized as scientific research programs, focused on the fundamental biology of cancer in general, and as disease-specific research programs centered on individual types of cancer, such as breast or lung cancer. Translational research, a hallmark of the institute, is finding new ways to integrate the extraordinary growth and understanding made in basic research with the ever-growing need for the development of new therapies and approaches in the clinic to a variety of cancers that have remained difficult to treat. To help translate discovery into clinical practice, the NYU Cancer Institute has five primary areas of investigation: cancer targets and novel therapeutics, community and environment, integrative health, molecular oncology/cancer genomics, and immune- and stem-cell-based therapies.
About NYU Langone Medical CenterNYU Langone Medical Center, a world-class, patient-centered, integrated, academic medical center, is one of the nation’s premier centers for excellence in clinical care, biomedical research and medical education. Located in the heart of Manhattan, NYU Langone is composed of four hospitals – Tisch Hospital, its flagship acute care facility; the Rusk Institute of Rehabilitation Medicine, the world’s first university-affiliated facility devoted entirely to rehabilitation medicine; the Hospital for Joint Diseases, one of only five hospitals in the nation dedicated to orthopaedics and rheumatology; and Hassenfeld Pediatric Center, a comprehensive pediatric hospital supporting a full array of children’s health services across the Medical Center – plus the NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history. The medical center’s tri-fold mission to serve, teach and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education and research. For more information, go to www.NYULMC.org.
RSS